Safe Wolverine

ROUND 06 // THE TAPE

BPC-157 TB-500 references: every claim, traced to source

The full citation register behind the matchup — peer-reviewed studies and reviews for each constituent, plus the FDA compounding records behind the access page.

Back to the researchThe access record

How to read this register

These BPC-157 TB-500 references are the complete source list for the matchup. Entries [1]-[7] are the primary mechanism and structural studies for each constituent; [8]-[10] are recent reviews that frame the evidence quality and the missing combination data; [11]-[13] are the FDA records behind the Wolverine legal status and 503A compounding page. Every quantitative claim across the site resolves to one of these. The numbered list below carries each citation with its DOI, PMID, or source URL.

  1. Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. ↗
  2. Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95:323-333. ↗
  3. Irobi E, et al. Structural basis of actin sequestration by thymosin-beta4: implications for WH2 proteins. EMBO J. 2004;23(18):3599-3608. ↗
  4. Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37-51. ↗
  5. Hsieh MJ, et al. Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway. Sci Rep. 2020;10:17078. ↗
  6. Philp D, et al. Thymosin beta4 promotes angiogenesis, wound healing, and hair follicle development. Mech Ageing Dev. 2004;125(2):113-115. ↗
  7. Esposito S, et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012;4(9):733-738. ↗
  8. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025. (36 studies, 35 preclinical and 1 human; no clinical safety data; evidence level IV-V; no mention of TB-500 or combination use.) ↗
  9. Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026. ↗
  10. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025. ↗
  11. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. (Category 2 entries for 'BPC-157' and 'Thymosin beta-4, fragment (LKKTETQ), also known as TB-500'; effective with the September 29, 2023 update to the nominated-substances list.) ↗
  12. U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. (Definitions of Category 1 and Category 2; the 503A/503B bulk-substance framework and bulks-list eligibility rules.) ↗
  13. U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. (Public calendar listing BPC-157 and TB-500 among bulk drug substances 'being considered for inclusion on the 503A Bulks List'; a scheduled discussion, not a decision.) ↗